pegsitacianine
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2021 (NCT04950166)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetOTHER
Diagnostic
Chemistry & pharmacology
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650497 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05576974 | Phase 2 | Jan 1, 2023 | The University of Texas, Dallas |
| NCT05048082 | Phase 2 | Nov 30, 2021 | OncoNano Medicine, Inc. |
| NCT04950166 | Phase 2 | Oct 31, 2021 | OncoNano Medicine, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| OncoNano Medicine, Inc. | For profit | 2 | 2 | 1 | 2021 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1